By binding to BCL-2, venetoclax disrupts its interaction with pro-apoptotic proteins like BAX, thereby promoting apoptosis in CLL cells, which often exhibit overexpression of BCL-2, which leads to resistance to cell death. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.